Literature DB >> 14557356

Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging.

M B Britten1, N D Abolmaali, B Assmus, R Lehmann, J Honold, J Schmitt, T J Vogl, H Martin, V Schächinger, S Dimmeler, A M Zeiher.   

Abstract

BACKGROUND: Experimental and initial clinical studies suggest that transplantation of circulating blood- (CPC) or bone marrow-derived (BMC) progenitor cells may beneficially affect postinfarction remodeling processes after acute myocardial infarction (AMI). To relate functional characteristics of the infused cells to quantitative measures of outcome at 4-month follow-up, we performed serial contrast-enhanced MRI and assessed the migratory capacity of the transplanted progenitor cells immediately before intracoronary infusion. METHODS AND
RESULTS: In 28 patients with reperfused AMI receiving either BMCs or CPCs into the infarct artery 4.7+/-1.7 days after AMI, serial contrast-enhanced MRI performed initially and after 4 months revealed a significant increase in global ejection fraction (from 44+/-10% to 49+/-10%; P=0.003), a decrease in end-systolic volume (from 69+/-26 to 60+/-28 mL; P=0.003), and unchanged end-diastolic volumes (122+/-34 versus 117+/-37 mL; P=NS). Infarct size, measured as late enhancement (LE) volume, decreased significantly, from 46+/-32 to 37+/-28 mL (P<0.05). There was a significant correlation between the reduction in LE volume and global ejection fraction improvement. The migratory capacity of transplanted cells as assessed ex vivo toward a gradient of vascular endothelial growth factor for CPCs and stromal cell derived factor-1 for BMCs was closely correlated with the reduction of LE volume. By multivariate analysis, migratory capacity remained the most important independent predictor of infarct remodeling.
CONCLUSIONS: Analysis of serial contrast-enhanced MRI suggests that intracoronary infusion of adult progenitor cells in patients with AMI beneficially affects postinfarction remodeling processes. The migratory capacity of the infused cells is a major determinant of infarct remodeling, disclosing a causal effect of progenitor cell therapy on regeneration enhancement.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557356     DOI: 10.1161/01.CIR.0000095788.78169.AF

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  121 in total

1.  CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction.

Authors:  Kentaro Jujo; Hiromichi Hamada; Atsushi Iwakura; Tina Thorne; Haruki Sekiguchi; Trevor Clarke; Aiko Ito; Sol Misener; Toshikazu Tanaka; Ekaterina Klyachko; Koichi Kobayashi; Jörn Tongers; Jérôme Roncalli; Yukio Tsurumi; Nobuhisa Hagiwara; Douglas W Losordo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  SPECT and PET to optimize cardiac stem cell therapy.

Authors:  Angel T Chan; M Roselle Abraham
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

3.  Panoramic view of the Fifth International Symposium on Stem Cell Therapy and Applied Cardiovascular Biotechnology, April 2008, Madrid (Spain).

Authors:  Adolfo Villa; Ricardo Sanz; M Eugenia Fernandez; Jaime Elizaga; Indrig Ludwig; Pedro L Sanchez; Francisco Fernandez-Aviles
Journal:  J Cardiovasc Transl Res       Date:  2008-09-19       Impact factor: 4.132

4.  Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products.

Authors:  Giuseppe Astori; Sabrina Soncin; Viviana Lo Cicero; Francesco Siclari; Daniel Sürder; Lucia Turchetto; Gianni Soldati; Tiziano Moccetti
Journal:  Am J Transl Res       Date:  2010-05-15       Impact factor: 4.060

5.  Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium.

Authors:  Prasanna Krishnamurthy; Melissa Thal; Suresh Verma; Eneda Hoxha; Erin Lambers; Veronica Ramirez; Gangjian Qin; Douglas Losordo; Raj Kishore
Journal:  Circ Res       Date:  2011-09-29       Impact factor: 17.367

6.  Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.

Authors:  Joshua M Barnett; Sandra Suarez; Gary W McCollum; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-26       Impact factor: 4.799

7.  Tracking stem cells for cardiovascular applications in vivo: focus on imaging techniques.

Authors:  Yingli Fu; Nicole Azene; Yi Xu; Dara L Kraitchman
Journal:  Imaging Med       Date:  2011-08-01

8.  Delivery and tracking of therapeutic cell preparations for clinical cardiovascular applications.

Authors:  R de Silva; R J Lederman
Journal:  Cytotherapy       Date:  2004       Impact factor: 5.414

Review 9.  Unchain my heart: the scientific foundations of cardiac repair.

Authors:  Stefanie Dimmeler; Andreas M Zeiher; Michael D Schneider
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

10.  Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1.

Authors:  Brendan Doyle; Paul Sorajja; Brian Hynes; Arun H S Kumar; Phillip A Araoz; Paul G Stalboerger; Dylan Miller; Cynthia Reed; Jeffrey Schmeckpeper; Shaohua Wang; Chunsheng Liu; Andre Terzic; David Kruger; Stephen Riederer; Noel M Caplice
Journal:  Stem Cells Dev       Date:  2008-10       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.